<p>For the first time in history, surgeons applied live stem cells directly onto the damaged spinal cord of an unborn baby — and the results have exceeded every expectation.</p>
<p>A Phase 1 clinical trial at <strong>UC Davis Health</strong>, published in early 2026, has shown that combining traditional fetal surgery for spina bifida with the application of <strong>placenta-derived mesenchymal stem cells (PMSCs)</strong> is not only safe, but yields outcomes that have left the medical community quietly astonished.</p>
<h2>What Is Spina Bifida?</h2>
<p>Spina bifida is a birth defect where the spinal column fails to close completely during fetal development. The most severe form — <strong>myelomeningocele</strong> — leaves part of the spinal cord exposed outside the body. Without intervention, affected children typically face paralysis below the lesion, chronic hydrocephalus (fluid on the brain) requiring a permanent shunt, and varying degrees of bowel and bladder dysfunction.</p>
<p>Fetal surgery to close the spine before birth — performed while the baby is still in the womb — has been available for over a decade, and it improves outcomes compared to postnatal repair. But the underlying nerve damage was always considered irreversible.</p>
<p>The UC Davis team asked: what if we could do more than close the wound?</p>
<h2>The CuRe Trial</h2>
<p>The <strong>CuRe Trial</strong> (Cellular Therapy for In-Utero Repair) enrolled six unborn babies diagnosed with myelomeningocele, whose surgeries were performed between July 2021 and December 2022. During each procedure, surgeons applied PMSCs — stem cells harvested from the baby's own mother's placenta — directly onto the exposed spinal cord before closing the wound.</p>
<p>The stem cells had been shown in animal studies to reduce inflammation, support nerve regeneration, and promote healing. This was the first time they had been used on a human fetus.</p>
<h2>The Results</h2>
<p>The outcomes were, in the researchers' own careful scientific language, exceptional:</p>
<ul> <li><strong>Zero safety concerns.</strong> No infections. No spinal fluid leaks. No abnormal tissue growth. No tumours. All surgeries successful. All wounds healed completely.</li> <li><strong>Hindbrain herniation reversed in all six infants.</strong> This brain abnormality — which in spina bifida typically causes the lower part of the brain to push down into the spinal canal — was observed on post-birth MRI scans to have reversed in every child in the trial.</li> <li><strong>No baby required a brain shunt</strong> before discharge from hospital. In standard care, a significant proportion of spina bifida babies require shunts. In this trial: none.</li> </ul>
<p>"The early results are really exciting," said the UC Davis team. "We're cautiously optimistic that this approach could improve outcomes in ways we haven't been able to achieve before."</p>
<h2>What Comes Next</h2>
<p>Long-term follow-up of the original six children is ongoing — they will be monitored until the age of six to assess motor function, bladder and bowel control, and neurological development.</p>
<p>But the results were strong enough that the <strong>FDA and an independent safety monitoring board</strong> have approved moving to Phase 2 — an expanded study involving 29 participants.</p>
<p>This is science doing what science is supposed to do: taking a problem once considered fixed, and finding a way through it.</p>
<p>Six children were born into a world where doctors had found something new to give them. That is not a small thing.</p>
<p><em>Sources: The Guardian (Feb 26, 2026) · UC Davis Health · Gizmodo · Healthcare in Europe · Shine Charity · The Lancet (Phase 1 published results)</em></p>
